#AHA25: CRISPR Therapeutics’ gene editing therapy halves cholesterol and triglycerides in early trialnews2025-11-10T15:25:01+00:00November 10th, 2025|Endpoints News|
Roche reports two Phase 3 wins for its BTK inhibitor in multiple sclerosisnews2025-11-10T12:30:39+00:00November 10th, 2025|Endpoints News|
#AHA25: Ionis claims curative potential for Tryngolza in severe triglyceride diseasenews2025-11-10T12:03:22+00:00November 10th, 2025|Endpoints News|
#AASLD25: Vir presents new hepatitis D data and ramps up bullish Phase 3 plansnews2025-11-09T23:15:42+00:00November 9th, 2025|Endpoints News|
#AHA25: Merck reports pivotal PCSK9 pill data in race to beat AstraZeneca to marketnews2025-11-09T22:00:40+00:00November 9th, 2025|Endpoints News|
FDA says it raised concerns about Biohaven’s ataxia study several times since it was proposednews2025-11-07T20:08:07+00:00November 7th, 2025|Endpoints News|
Gilead’s Trodelvy fails Phase 3 breast cancer studynews2025-11-07T20:02:05+00:00November 7th, 2025|Endpoints News|
#SITC25: Akeso, Summit’s PD-1xVEGF drug extends life in China lung cancer studynews2025-11-07T16:30:31+00:00November 7th, 2025|Endpoints News|
ObesityWeek rode the momentum of the field’s most dramatic week in monthsnews2025-11-07T14:30:19+00:00November 7th, 2025|Endpoints News|
#AASLD25: Rivus’ MASH drug cuts liver fat, preserves muscle in mid-stage trialnews2025-11-07T13:00:37+00:00November 7th, 2025|Endpoints News|
